- Home
- FORR vs MBX Comparison
FORR vs MBX Comparison
Compare FORR & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- MBX
- Stock Information
- Founded
- FORR 1983
- MBX 36
- Country
- FORR United States
- MBX United States
- Employees
- FORR N/A
- MBX N/A
- Industry
- FORR Diversified Commercial Services
- MBX
- Sector
- FORR Consumer Discretionary
- MBX
- Exchange
- FORR Nasdaq
- MBX NYSE
- Market Cap
- FORR 293.9M
- MBX 347.9M
- IPO Year
- FORR 1996
- MBX 2024
- Fundamental
- Price
- FORR $11.93
- MBX $10.88
- Analyst Decision
- FORR
- MBX Strong Buy
- Analyst Count
- FORR 0
- MBX 4
- Target Price
- FORR N/A
- MBX $37.25
- AVG Volume (30 Days)
- FORR 77.6K
- MBX 319.2K
- Earning Date
- FORR 02-11-2025
- MBX 03-07-2025
- Dividend Yield
- FORR N/A
- MBX N/A
- EPS Growth
- FORR N/A
- MBX N/A
- EPS
- FORR N/A
- MBX N/A
- Revenue
- FORR $432,470,000.00
- MBX N/A
- Revenue This Year
- FORR N/A
- MBX N/A
- Revenue Next Year
- FORR $0.15
- MBX N/A
- P/E Ratio
- FORR N/A
- MBX N/A
- Revenue Growth
- FORR N/A
- MBX N/A
- 52 Week Low
- FORR $11.79
- MBX $8.63
- 52 Week High
- FORR $21.91
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- FORR 21.17
- MBX N/A
- Support Level
- FORR $11.79
- MBX N/A
- Resistance Level
- FORR $13.33
- MBX N/A
- Average True Range (ATR)
- FORR 0.71
- MBX 0.00
- MACD
- FORR -0.28
- MBX 0.00
- Stochastic Oscillator
- FORR 3.84
- MBX 0.00
About FORR Forrester Research Inc.
Forrester Research Inc is a United States-based company that provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.